Durable knockdown and protection from HIV transmission in humanized mice treated with gel-formulated CD4 aptamer-siRNA chimeras

Molecular Therapy

Volumn 21, Issue 7, 2013, Pages 1378-1389

  Wheeler, Lee Adam ^a,b   Vrbanac, Vladimir ^c   Trifonova, Radiana ^a,b   Brehm, Michael A ^d   Gilboa Geffen, Adi ^a,b   Tanno, Serah ^c   Greiner, Dale L ^d   Luster, Andrew D ^c   Tager, Andrew M ^c   Lieberman, Judy ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; CD4 APTAMER; CD4 APTAMER-SIRNA CHIMERAS; CHEMOKINE RECEPTOR CCR5; GAG PROTEIN; HYDROXYETHYLCELLULOSE; MICROBICIDE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VIF PROTEIN;

ARTICLE; CD4+ T LYMPHOCYTE; CHIMERA; DRUG FORMULATION; DRUG MECHANISM; DRUG TARGETING; EXPLANT; GEL; GENE SILENCING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN TISSUE; MOUSE; NONHUMAN; PROTEIN TARGETING; RNA INTERFERENCE; SEXUAL TRANSMISSION; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS TRANSMISSION;

MUS;

EID: 84879691173     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.77     Document Type: Article

References (50)

1. Abdool Karim, Q, Abdool Karim, SS, Frohlich, JA, Grobler, AC, Baxter, C, Mansoor, LE et al.; CAPRISA 004 Trial Group. (2010). Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329: 1168-1174.
2. Celum, C and Baeten, JM (2012). Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence. Curr Opin Infect Dis 25: 51-57.
3. McGowan, I (2010). Microbicides for HIV prevention: reality or hope? Curr Opin Infect Dis 23: 26-31.
4. de Fougerolles, A, Vornlocher, H P, Maraganore, J and Lieberman, J (2007). Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 6: 443-453. (Pubitemid 47064567)
5. Song, E, Lee, SK, Dykxhoorn, DM, Novina, C, Zhang, D, Crawford, K et al. (2003). Sustained small interfering RNA-mediated human immunodefciency virus type 1 inhibition in primary macrophages. J Virol 77: 7174-7181. (Pubitemid 36734486)
6. Novina, CD, Murray, MF, Dykxhoorn, DM, Beresford, PJ, Riess, J, Lee, SK et al. (2002). siRNA-directed inhibition of HIV-1 infection. Nat Med 8: 681-686. (Pubitemid 34778720)
7. Anderson, J, Banerjea, A, Planelles, V and Akkina, R (2003). Potent suppression of HIV type 1 infection by a short hairpin anti-CXCR4 siRNA. AIDS Res Hum Retroviruses 19: 699-706. (Pubitemid 37047095)
8. Capodici, J, Karikó, K and Weissman, D (2002). Inhibition of HIV-1 infection by small interfering RNA-mediated RNA interference. J Immunol 169: 5196-5201. (Pubitemid 35217190)
9. Coburn, GA and Cullen, BR (2002). Potent and specifc inhibition of human immunodefciency virus type 1 replication by RNA interference. J Virol 76: 9225-9231. (Pubitemid 34919881)
10. Jacque, JM, Triques, K and Stevenson, M (2002). Modulation of HIV-1 replication by RNA interference. Nature 418: 435-438. (Pubitemid 34826845)
11. Lee, NS, Dohjima, T, Bauer, G, Li, H, Li, MJ, Ehsani, A et al. (2002). Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol 20: 500-505. (Pubitemid 34495938)
12. Kumar, P, Ban, HS, Kim, SS, Wu, H, Pearson, T, Greiner, DL et al. (2008). T cell-specifc siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 134: 577-586.
13. Palliser, D, Chowdhury, D, Wang, QY, Lee, SJ, Bronson, RT, Knipe, DM et al. (2006). An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature 439: 89-94. (Pubitemid 43053634)
14. Wheeler, LA, Trifonova, R, Vrbanac, V, Basar, E, McKernan, S, Xu, Z et al. (2011). Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. J Clin Invest 121: 2401-2412.
15. Wu, Y, Navarro, F, Lal, A, Basar, E, Pandey, RK, Manoharan, M et al. (2009). Durable protection from Herpes Simplex Virus-2 transmission following intravaginal application of siRNAs targeting both a viral and host gene. Cell Host Microbe 5: 84-94.
16. Song, E, Lee, SK, Wang, J, Ince, N, Ouyang, N, Min, J et al. (2003). RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 9: 347-351. (Pubitemid 36362792)
17. Margolis, L and Shattock, R (2006). Selective transmission of CCR5-utilizing HIV-1: the 'gatekeeper' problem resolved? Nat Rev Microbiol 4: 312-317.
18. Haase, AT (2010). Targeting early infection to prevent HIV-1 mucosal transmission. Nature 464: 217-223.
19. Veazey, RS, Klasse, PJ, Ketas, TJ, Reeves, JD, Piatak, M Jr, Kunstman, K et al. (2003). Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodefciency virus infection or prevent simian-human immunodefciency virus infection. J Exp Med 198: 1551-1562. (Pubitemid 37467169)
20. Tsamis, F, Gavrilov, S, Kajumo, F, Seibert, C, Kuhmann, S, Ketas, T et al. (2003). Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodefciency virus type 1 entry. J Virol 77: 5201-5208. (Pubitemid 36460934)
21. Lederman, MM, Veazey, RS, Offord, R, Mosier, DE, Dufour, J, Mefford, M et al. (2004). Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 306: 485-487. (Pubitemid 39372448)
22. Veazey, RS, Ketas, TJ, Dufour, J, Moroney-Rasmussen, T, Green, LC, Klasse, PJ et al. (2010). Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. J Infect Dis 202: 739-744.
23. Peer, D, Zhu, P, Carman, CV, Lieberman, J and Shimaoka, M (2007). Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc Natl Acad Sci USA 104: 4095-4100. (Pubitemid 47181584)
24. Song, E, Zhu, P, Lee, SK, Chowdhury, D, Kussman, S, Dykxhoorn, DM et al. (2005). Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 23: 709-717. (Pubitemid 41716361)
25. Stull, RA and Szoka, FC Jr (1995). Antigene, ribozyme and aptamer nucleic acid drugs: progress and prospects. Pharm Res 12: 465-483.
26. Held, DM, Kissel, JD, Patterson, JT, Nickens, DG and Burke, DH (2006). HIV-1 inactivation by nucleic acid aptamers. Front Biosci 11: 89-112. (Pubitemid 43253477)
27. Dassie, J P, Liu, XY, Thomas, GS, Whitaker, RM, Thiel, KW, Stockdale, KR et al. (2009). Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol 27: 839-849.
28. McNamara, JO 2nd, Andrechek, ER, Wang, Y, Viles, KD, Rempel, RE, Gilboa, E et al. (2006). Cell type-specifc delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 24: 1005-1015. (Pubitemid 44215395)
29. Zhou, J, Swiderski, P, Li, H, Zhang, J, Neff, C P, Akkina, R et al. (2009). Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res 37: 3094-3109.
30. Davis, KA, Lin, Y, Abrams, B and Jayasena, SD (1998). Staining of cell surface human CD4 with 2'-F-pyrimidine-containing RNA aptamers for fow cytometry. Nucleic Acids Res 26: 3915-3924. (Pubitemid 28401340)
31. Brainard, DM, Seung, E, Frahm, N, Cariappa, A, Bailey, CC, Hart, WK et al. (2009). Induction of robust cellular and humoral virus-specifc adaptive immune responses in human immunodefciency virus-infected humanized BLT mice. J Virol 83: 7305-7321.
32. Shultz, LD, Ishikawa, F and Greiner, DL (2007). Humanized mice in translational biomedical research. Nat Rev Immunol 7: 118-130. (Pubitemid 46174859)
33. Denton, PW, Estes, JD, Sun, Z, Othieno, FA, Wei, BL, Wege, AK et al. (2008). Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med 5: e16.
34. Sun, Z, Denton, PW, Estes, JD, Othieno, FA, Wei, BL, Wege, AK et al. (2007). Intrarectal transmission, systemic infection, and CD4+ T cell depletion in humanized mice infected with HIV-1. J Exp Med 204: 705-714. (Pubitemid 46631601)
35. Tien, D, Schnaare, RL, Kang, F, Cohl, G, McCormick, TJ, Moench, TR et al. (2005). In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. AIDS Res Hum Retroviruses 21: 845-853. (Pubitemid 43150316)
36. Hladik, F and Doncel, GF (2010). Preventing mucosal HIV transmission with topical microbicides: challenges and opportunities. Antiviral Res 88 Suppl 1: S3-S9.
37. Neff, CP, Kurisu, T, Ndolo, T, Fox, K and Akkina, R (2011). A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice. PLoS ONE 6: e20209.
38. Neff, CP, Zhou, J, Remling, L, Kuruvilla, J, Zhang, J, Li, H et al. (2011). An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci Transl Med 3: 66ra6.
39. Boden, D, Pusch, O, Lee, F, Tucker, L and Ramratnam, B (2003). Human immunodefciency virus type 1 escape from RNA interference. J Virol 77: 11531-11535. (Pubitemid 37271651)
40. Tary-Lehmann, M, Lehmann, PV, Schols, D, Roncarolo, MG and Saxon, A (1994). Anti-SCID mouse reactivity shapes the human CD4+ T cell repertoire in hu-PBL-SCID chimeras. J Exp Med 180: 1817-1827.
41. Kalscheuer, H, Danzl, N, Onoe, T, Faust, T, Winchester, R, Goland, R et al. (2012). A model for personalized in vivo analysis of human immune responsiveness. Sci Transl Med 4: 125ra30.
42. Lan, P, Tonomura, N, Shimizu, A, Wang, S and Yang, YG (2006). Reconstitution of a functional human immune system in immunodefcient mice through combined human fetal thymus/liver and CD34+ cell transplantation. Blood 108: 487-492. (Pubitemid 44061346)
43. Douek, DC, Brenchley, JM, Betts, MR, Ambrozak, DR, Hill, BJ, Okamoto, Y et al. (2002). HIV preferentially infects HIV-specifc CD4+ T cells. Nature 417: 95-98. (Pubitemid 34498823)
44. Royce, RA, Seña, A, Cates, W Jr and Cohen, MS (1997). Sexual transmission of HIV. N Engl J Med 336: 1072-1078. (Pubitemid 27163861)
45. Pabst, KM, Reichart, CA, Knud-Hansen, CR, Wasserheit, JN, Quinn, TC, Shah, K et al. (1992). Disease prevalence among women attending a sexually transmitted disease clinic varies with reason for visit. Sex Transm Dis 19: 88-91. (Pubitemid 23101888)
46. Wasserheit, JN (1992). Epidemiological synergy. Interrelationships between human immunodefciency virus infection and other sexually transmitted diseases. Sex Transm Dis 19: 61-77. (Pubitemid 23101885)
47. Rich, JD, Ramratnam, B and Flanigan, TP (1997). Triple combination antiretroviral prophylaxis for needlestick exposure to HIV. Infect Control Hosp Epidemiol 18: 161.
48. Mayer, KH and Venkatesh, KK (2010). Antiretroviral therapy as HIV prevention: status and prospects. Am J Public Health 100: 1867-1876.
49. Zhou, J, Neff, C P, Swiderski, P, Li, H, Smith, DD, Aboellail, T et al. (2013). Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridge. Mol Ther 21: 192-200.
50. Armbruster, DA and Pry, T (2008). Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev 29 Suppl 1: S49-S52.